Solifenacin

Solifenacin
Clinical data
Trade namesVesicare, Vesicare LS
Other namesYM905
AHFS/Drugs.comMonograph
MedlinePlusa605019
License data
Pregnancy
category
  • AU: B3
Routes of
administration
By mouth
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
Pharmacokinetic data
Bioavailability90%
Protein binding98%
MetabolismCYP3A4
MetabolitesGlucuronide, N-oxide, others
Elimination half-life45 to 68 hours
ExcretionKidney (69.2%) and fecal (22.5%)
Identifiers
  • (3R)-1-Azabicyclo[2 2 2]oct-3-yl (1S)-1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H26N2O2
Molar mass362.473 g·mol−1
3D model (JSmol)
  • C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5
  • InChI=1S/C23H26N2O2/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19/h1-9,18,21-22H,10-16H2/t21-,22-/m0/s1 ☒N
  • Key:FBOUYBDGKBSUES-VXKWHMMOSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Solifenacin, sold as the brand name Vesicare[a] among others, is a medicine used to treat overactive bladder and neurogenic detrusor overactivity (NDO).[1][2] It may help with incontinence, urinary frequency, and urinary urgency.[3]

Benefits appear similar to other medications in the class.[4] It is taken by mouth.[1]

Common side effects include dry mouth, constipation, and urinary tract infection.[1][2] Severe side effects may include urinary retention, QT prolongation, hallucinations, glaucoma, and anaphylaxis.[1][3][2] It is unclear if use is safe during pregnancy.[1] It is of the antimuscarinic class and works by decreasing bladder contractions.[1]

Solifenacin was approved for medical use in the United States in 2004.[1][2][5] In 2022, it was the 210th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[6][7]


Cite error: There are <ref group=lower-alpha> tags or {{efn}} templates on this page, but the references will not show without a {{reflist|group=lower-alpha}} template or {{notelist}} template (see the help page).

  1. ^ a b c d e f g "Solifenacin Succinate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists.
  2. ^ a b c d "FDA Approves First Treatment for a Form of Bladder Dysfunction in Pediatric Patients as Young as 2 Years of Age". U.S. Food and Drug Administration (FDA) (Press release). 26 May 2020. Retrieved 26 May 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  3. ^ a b British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 761. ISBN 9780857113382.
  4. ^ "[93] Are claims for newer drugs for overactive bladder warranted?". Therapeutics Initiative. 22 April 2015. Retrieved 17 March 2019.
  5. ^ Cite error: The named reference FDA approval was invoked but never defined (see the help page).
  6. ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  7. ^ "Solifenacin Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.